CRISPR Therapeutics (NASDAQ: CRSP) has been making headlines lately as a result of its groundbreaking gene-editing collaboration with Vertex Pharmaceuticals (NASDAQ: VRTX). The backstory is that the two companies recently filed for a spate of regulatory approvals for the CRISPR/Cas9 gene-edited product, exa-cel, as a functional cure for two rare blood disorders, sickle cell disease and transfusion-dependent beta thalassemia.

What arguably hasn't been appreciated, however, is CRISPR's other clinical assets in immuno-oncology, regenerative medicine, and in vivo therapeutics. Wall Street has essentially assigned these other programs zero value, evinced by the fact that CRISPR's stock is trading at under three times its last stated cash position. In fact, this meager valuation arguably doesn't even reflect the full commercial potential of exa-cel. Wall Street's pessimism might represent a once-in-a-lifetime opportunity for savvy investors.

Image Source: Getty Images.

Continue reading

Source Fool.com